A detailed history of New Edge Advisors, LLC transactions in Lantern Pharma Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 157,124 shares of LTRN stock, worth $507,510. This represents 0.01% of its overall portfolio holdings.

Number of Shares
157,124
Previous 160,532 2.12%
Holding current value
$507,510
Previous $1.41 Million 48.09%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$3.91 - $9.51 $13,325 - $32,410
-3,408 Reduced 2.12%
157,124 $733,000
Q1 2024

May 14, 2024

SELL
$3.73 - $10.65 $20,291 - $57,936
-5,440 Reduced 3.28%
160,532 $1.41 Million
Q4 2023

Feb 13, 2024

SELL
$2.48 - $4.39 $10,066 - $17,819
-4,059 Reduced 2.39%
165,972 $710,000
Q3 2023

Nov 14, 2023

SELL
$3.41 - $5.51 $4,889 - $7,901
-1,434 Reduced 0.84%
170,031 $579,000
Q2 2023

Aug 14, 2023

SELL
$4.56 - $6.02 $2,963 - $3,912
-650 Reduced 0.38%
171,465 $967,000
Q1 2023

May 12, 2023

SELL
$4.3 - $6.2 $3,108 - $4,482
-723 Reduced 0.42%
172,115 $831,000
Q4 2022

Feb 14, 2023

BUY
$4.19 - $6.04 $7,621 - $10,986
1,819 Added 1.06%
172,838 $1.04 Million
Q3 2022

Nov 14, 2022

BUY
$4.59 - $6.5 $4,805 - $6,805
1,047 Added 0.62%
171,019 $817,000
Q2 2022

Aug 09, 2022

BUY
$4.82 - $7.45 $968 - $1,497
201 Added 0.12%
169,972 $971,000
Q1 2022

May 13, 2022

BUY
$5.6 - $8.22 $14,923 - $21,906
2,665 Added 1.59%
169,771 $1.21 Million
Q4 2021

Feb 17, 2022

BUY
$7.11 - $11.04 $79,966 - $124,166
11,247 Added 7.22%
167,106 $1.33 Million
Q3 2021

Oct 29, 2021

BUY
$10.53 - $14.93 $47,837 - $67,826
4,543 Added 3.0%
155,859 $1.74 Million
Q2 2021

Jul 22, 2021

BUY
$12.94 - $19.89 $1.96 Million - $3.01 Million
151,316 New
151,316 $2.21 Million

Others Institutions Holding LTRN

About Lantern Pharma Inc.


  • Ticker LTRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 10,830,900
  • Market Cap $35M
  • Description
  • Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...
More about LTRN
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.